Company profile
CARTESIAN THERAPEUTICS, INC.
NASDAQ:RNACBiotechnology: Pharmaceutical Preparations
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03448978 | phase1 | terminated | 2018-03-08 | 2021-04-19 | Cartesian Therapeutics | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma |
| NCT04146051 | phase2 | active_not_recruiting | 2019-12-04 | 2026-01-05 | Cartesian Therapeutics | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
| NCT04816526 | phase2 | terminated | 2021-12-01 | 2022-08-04 | Cartesian Therapeutics | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy |
| NCT07089121 | phase1_2 | recruiting | 2026-01-14 | 2027-12-01 | Cartesian Therapeutics | Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders |
| NCT06038474 | phase2 | active_not_recruiting | 2024-02-12 | 2026-12-01 | Cartesian Therapeutics | Descartes-08 for Patients With Systemic Lupus Erythematosus |
FDA applications (0)
No records yet.